Searchable abstracts of presentations at key conferences in endocrinology

ea0016p508 | Obesity | ECE2008

NCEP-ATP-III defined metabolic syndrome, type 2 diabetes mellitus and prevalence of hypogonadism in male patients with sexual dysfunction

Corona Giovanni , Mannucci Edoardo , Petrone Luisa , Balercia Giancarlo , Paggi Federica , Fisher Alessandra , Lotti Francesco , Chiarini Valerio , Forti Gianni , Maggi Mario

Objectives: Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are characterized by insulin resistance and often associated with male hypogonadism. To discriminate the specific contribution of T2DM and MetS to male hypogonadism.Design and methods: A consecutive series of 1134 (mean age 52.1±13 years) male patients with sexual dysfunction was studied. Several hormonal and biochemical parameters were studied along with ANDROTEST, a 12-item ...

ea0014p194 | (1) | ECE2007

A comparison of NCEP-ATP-III and IDF metabolic syndrome definitions with relation to metabolic syndrome associated sexual dysfunction

Corona Giovanni , Mannucci Edoardo , Petrone Luisa , Lotti Francesco , Fisher Alessandra D , Balercia Giancarlo , Chairini Valerio , Forti Gianni , Maggi Mario

Objectives: The aim of present study was to verify possible differences in the prevalence of vasculogenic ED and hypogonadism comparing two distinct new definitions of MetS, as National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATPIII) and International diabetes Federation (IDF) in patients with sexual dysfunction.Methods: Several hormonal, biochemical and instrumental (penile doppler ultrasound) parameters were studied. ANDROTEST S...

ea0014p611 | (1) | ECE2007

Androtest: a structured interview for the screening of hypogonadism in patients with sexual dysfunction

Corona Giovanni , Petrone Luisa , Mannucci Edoardo , Fisher Alessandra D , Chairini Valerio , Balercia Giancarlo , Forti Gianni , Maggi Mario

Objectives: Detecting hypogonadism is crucial in patients with sexual dysfunctions because hypogonadism can have a causal role for them and testosterone (T) substitution represents a milestone for the therapy. At present, three different inventories have been developed for screening of hypogonadism in aging male. All these instruments demonstrated a good sensitivity but low specificity. No inventories are available for the screening of hypogonadism in patients with sexual dysf...

ea0011p652 | Reproduction | ECE2006

Psycho-biological correlates of delayed ejaculation in male patients with sexual dysfunctions

Corona G , Petrone L , Mannucci E , Fisher AD , Balercia G , Giommi R , Chiarini V , Forti G , Maggi M

Introduction and objectives: Pathogenesis of delayed ejaculation (DE) is rather unknown, although the contribution of various psychological, marital, hormonal and neurological factors has been advocated.Methods: In this study we systematically investigated the relative relevance of the aforementioned factors in a large sample (1632) of men, seeking medical help for sexual dysfunction. Delayed ejaculation was defined according to Kaplan criteria. In parti...

ea0007p34 | Diabetes, metabolism and cardiovascular | BES2004

The effect of DHT on the regulation of the renin angiotensin system in human abdominal subcutaneous adipocytes: implications for PCOS

Harte A , Fowler A , Rodriguez-Cuenca S , Chetty R , Fisher F , Anderson L , Roca P , Kumar S , Matyka K , McTernan P

The renin-angiotensin system (RAS) is a key factor in the regulation of blood pressure and therefore its' blockade may reduce the vascular complications which arise with polycystic ovary syndrome (PCOS). Adipose tissue expresses all the components of the RAS system that includes the pre-prohormone angiotensinogen (AGT) and its' active metabolite angiotensin II (ANG II), which mediates vasoconstriction and electrolyte balance and as such may contribute to obesity associated hyp...

ea0056p667 | Neuroendocrinology | ECE2018

Does gender affirming hormone therapy affect anger proneness in transgender persons?

Defreyne Justine , Elaut Els , Kreukels Baudewijntje , Heylens Gunter , Schreiner Thomas , Fisher Alessandra Daphne , Heijer Martin Den , T'Sjoen Guy

Introduction: Anger is an emotional state of feelings varying from mild irritation to intense rage, whereas aggression implies externalizing angry emotions through destructive/ punitive behavior towards other persons/objects. Although research on the relationship between testosterone and aggression is inconclusive, the WPATH SOC 7 guidelines have warned for an increase in aggression in transgender men (TM) taking testosterone treatment.Aims:<p class=...

ea0071010 | Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI) | BES2020

Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: A prospective cohort study (ENIGI)

J Defreyne , Y Vanwonterghem , S Collet , S Iwamoto , CM Wiepjes , AD Fisher , T Schreiner , M Den Heijer , G T'Sjoen

Background: Previous cross-sectional studies have described amenorrhea in cohorts of transgender men on intramuscular or subcutaneous testosterone injections. It remains uncertain which testosterone preparations most effectively suppress vaginal bleeding and when amenorrhea occurs after testosterone initiation.Aim: To investigate the clinical effects of various testosterone preparations on vaginal bleeding and spotting in transgender men.<p class="ab...

ea0013p19^ | Endocrine tumours and neoplasia | SFEBES2007

Genetic background influences expression of Multiple Endocrine Neoplasia type 1 (MEN1) mutation, implicating a role for genetic modifiers

Lemos Manuel , Harding Brian , Thakker Rajesh

The Multiple Endocrine Neoplasia type 1 (MEN1) gene is located on chromosome 11q13 and patients with mutations develop parathyroid, pancreatic and pituitary tumours. MEN1 mutations also cause familial isolated primary hyperparathyroidism (FIHP) and the same MEN1 mutations, in different families, can cause either FIHP or MEN1. This emphasises the importance of genetic background in altering the expression of a mutation, and suggests the presence of genetic ...

ea0089c25 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Evaluation of 68Ga-DOTATATE PET After Two Cycles of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Heying Duan , Hong Song , Valentina Ferri , George Fisher , Shagufta Shaheen , Jagruti Sha , Judy Nguyen , Farshad Moradi , Ben Franc , Guido Davidzon , Andrei Iagaru , Aparici Carina Mari

Background: We aimed to evaluate the added information provided by 68Ga-DOTATATE PET after two cycles of peptide receptor radionuclide therapy (PRRT) in patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NET).Methods: In this retrospective study, 105 patients (54 women and 51 men, 62.5&pm;10.5-year-old) with progressive NET treated with at least two cycles of 177Lu-DOTATATE were included. All patients had <...

ea0089c43 | Clinical – Surgery/Applied Pathology | NANETS2022

Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

S Lui Michael , B Fisher Sarah , G Grubbs Elizabeth , D Perrier Nancy , G Waguespack Steven , Varghese Jeena , A Habra Mouhammed , Jimenez Camilo , H Graham Paul

Background: Sympathetic pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors associated with excess catecholamine production. Routine biochemical and imaging surveillance to monitor for recurrence and metastasis is recommended. However, there is limited data describing optimal surveillance approaches and post-operative biochemical thresholds for detecting recurrences or metastases. This study sought to correlate biochemical and imaging surveillance with ...